Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Shares Outstanding (Weighted Average) (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Shares Outstanding (Weighted Average) for 7 consecutive years, with $86.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 29.12% to $86.7 million in Q4 2025 year-over-year; TTM through Nov 2025 was $86.7 million, a 29.12% increase, with the full-year FY2025 number at $86.7 million, up 29.12% from a year prior.
  • Shares Outstanding (Weighted Average) was $86.7 million for Q4 2025 at Nurix Therapeutics, up from $83.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $86.7 million in Q4 2025 to a low of $38.8 million in Q1 2021.
  • A 5-year average of $58.1 million and a median of $54.3 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): surged 1073.79% in 2021, then grew 1.62% in 2024.
  • Nurix Therapeutics' Shares Outstanding (Weighted Average) stood at $42.9 million in 2021, then increased by 13.32% to $48.6 million in 2022, then rose by 11.79% to $54.3 million in 2023, then grew by 23.52% to $67.1 million in 2024, then rose by 29.12% to $86.7 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Shares Outstanding (Weighted Average) are $86.7 million (Q4 2025), $83.9 million (Q3 2025), and $83.9 million (Q2 2025).